Costos por órdenes y la fijación de precio en la empresa textil del distrito San Juan de Lurigancho, Año 2018

El presente trabajo de investigación que tiene como título: Costos por ordénes y la fijacíon de precio en una empresa textíl del distrito de San Juan de Lurigancho, año 2018. Se ha establecido como objetivo principal; Determinar el nivel de relacíon entre el costo por orden y fijacíon de precios en empresa textíl del distrito de San Juan de Lurigancho año 2018. La hipótesis principal fue: Exíste relacíon entre costo por ordénes y fijacíon de precios una empresa textíl del distrito de San Juan de Lurigancho año 2018. Respecto a la metodología, la investigación realizada es aplicada, y el diseño es de tipo descriptivo y correlacíonal, cuantitativo, no experimental y la técnica utilizada es estudio de caso. Las variables identificadas como independientes son los costos por ordénes, mientras la variable dependiente es la fijacíon de precios. La muestra será 28 ordénes de trabajo. Finalizando la investigación, se ha confirmado las hipótesis planteadas en donde efectivamente el costo por orden se relacíona directamente con la fijacíon de precio de la empresa en estudio. Y por ello, se han permitido realizar las conclusiones y recomendaciones respectivas con la finalidad de que todos aquellos involucrados a este sector de negocio tomen conciencia, responsabilidad y acciones oportunas para crecer en este mercado tan competitivo

Evaluando el rendimiento académico

En las universidades la deserción estudiantil ha originado numerosos estudios y no pocos debates. El informe de la Comisión ad hoc (2005) de la UNT, revela excesiva permanencia y alta deserción. En una primera etapa, se analizó el rendimiento académico en el ciclo básico de la Facultad de Bioquímica de la UNT (Correa Zeballos, Chahar, Holgado, Figueroa, Sued, Nieva, 2006) identificándose factores asociados a esta problemática. En una segunda etapa se plantea como objetivo mostrar una metodología de estudio del desempeño académico en toda la carrera, tratando de determinar si los factores identificados son los mismos o difieren total o parcialmente. En esta presentación se hace el seguimiento de la cohorte 1997, utilizando una metodología de estudio de cohorte retrospectivo y aplicando distintos índices y tasas, de donde se infiere que el rendimiento académico de la cohorte analizada no se ajusta a los tiempos previstos en el plan de estudio, revelando baja tasa de egreso. Esto nos permitirá, proponer nuevas estrategias de enseñanza, particularmente de la Matemática por su carácter formativo

Preliminary Study on the Effect of an Early Physical Therapy Intervention after Sentinel Lymph Node Biopsy: A Multicenter Non-Randomized Controlled Trial

Selective sentinel lymph node biopsy (SLNB) represents a minimally invasive surgery in patients with breast cancer. The purpose of this study was to explore the possible effect of an early physiotherapy intervention for the recovery of the upper limb and the surgical scars after SLNB in comparison with usual care. A total of 40 patients were enrolled in either the control group (n = 20) or the experimental group (n = 20). The intervention group performed an early physiotherapy program based on functional exercises, scar manual therapy, and educational tips. The control group received usual care. Shoulder range of motion (ROM), grip strength, upper limb pain and disability (SPADI), scar recovery (POSAS), myofascial adhesions (MAP-BC), quality of life (EORTCQLA-BR-23) and the presence of axillary web syndrome (AWS) and lymphoedema were assessed at baseline and immediately after intervention. A follow-up period of 6 months was performed for lymphoedema surveillance. Between groups significant differences in favor of the intervention were found for ROM (r = 0.43), grip strength (r = 0.32), SPADI (d = 0.45), POSAS (d = 1.28), MAP-BC (d = 1.82) and EORTCQLQ-BR 23 general function subscale (d = 0.37) (p < 0.05 for all variables). Our results suggest that an early physical therapy program seems to be more effective than usual care in women after SLNB. However, results should be interpreted with caution and future randomized trial with a larger sample size is neededThis research was partially supported by ICPFA. Grant number 04722/19P/MA. The funder had no role in the design of the study and collection, analysis, and interpretation of data, and in writing the manuscript. Partial funding for open access charge: Universidad de Málag

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment

Recently, metastatic renal cell carcinoma (mRCC) treatment has changed dramatically with the onset of new therapies against molecular targets replacing immunotherapy as standard treatment. We report the case of a 49-year-old patient with a moderately differentiated renal clear cell carcinoma without extracapsular extension who underwent radical nephrectomy. Eight months after surgery, he developed a thyroid metastasis which was also treated surgically with a hemithyroidectomy. Seventy-five months after nephrectomy, the patient presented an upper gastrointestinal bleeding due to a duodenal metastasis that infiltrates the head of the pancreas. The treatment applied was surgery by duodenopancreatectomy, with positive surgical margins in the pathologic study. In addition to this, the extension study showed lung metastases requiring initiation of systemic treatment with sunitinib. The patient presented an excellent response to treatment, showing complete clinical and radiological response at 5 months of treatment (RECIST criteria) and a disease-free survival of 48 months until now, without evidence of toxicity. RCC has the potential to metastasize to almost any location, but thyroid and duodenal metastases in RCC are extremely rare. Moreover, this case also highlights the good responses that can be achieved in terms of disease-free survival, low toxicity and quality of life in this new era of therapies against molecular targets

Flexible Heuristics for Supporting Recommendations Within an AI Platform Aimed at Non-expert Users

The use of Machine Learning (ML) to resolve complex tasks has become popular in several contexts. While these approaches are very effective and have many related benefits, they are still very tricky for the general audience. In this sense, expert knowledge is crucial to apply ML algorithms properly and to avoid potential issues. However, in some situations, it is not possible to rely on experts to guide the development of ML pipelines. To tackle this issue, we present an approach to provide customized heuristics and recommendations through a graphical platform to build ML pipelines, namely KoopaML, focused on the medical domain.With this approach, we aim not only at providing an easy way to apply ML for non-expert users, but also at providing a learning experience for them to understand how these methods work

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. However, the risk of false positive achievements was not controlled in these early phase analyses. We propose to preplan NI analyses in superiority-based Simon's two-stage designs to control type I and II error rates. Simulations have been proposed to assess the control of type I and II errors rates with this method. A total of 12,768 two-stage Simon's design trials were constructed based on different assumptions of rejection response probability, desired response probability, type I and II errors, and NI margins. P-value and type II error were calculated with stochastic ordering using Uniformly Minimum Variance Unbiased Estimator. Type I and II errors were simulated using the Monte Carlo method. The agreement between calculated and simulated values was analyzed with Bland-Altman plots. We observed the same level of agreement between calculated and simulated type I and II errors from both two-stage Simon's superiority designs and designs in which NI analysis was allowed. Different examples has been proposed to explain the utility of this method. Inclusion of NI analysis in superiority-based single-arm clinical trials may be useful for weighing additional factors such as safety, pharmacokinetics, pharmacodynamic, and biomarker data while assessing early efficacy. Implementation of this strategy can be achieved through simple adaptations to existing designs for one-arm phase II clinical trials

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Abstract Background Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, who historically have poorer prognosis among patients with NSCLC. Patients and methods Patients were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks) until progression or discontinuation. The primary end point of each study was OS. Patients with baseline liver metastases were pooled across studies by treatment for subgroup analyses. Results After 40.3 months' minimum follow-up in CheckMate 017 and 057, nivolumab continued to show an OS benefit versus docetaxel: estimated 3-year OS rates were 17% [95% confidence interval (CI), 14% to 21%] versus 8% (95% CI, 6% to 11%) in the pooled population with squamous or nonsquamous NSCLC. Nivolumab was generally well tolerated, with no new safety concerns identified. Of 854 randomized patients across both studies, 193 had baseline liver metastases. Nivolumab resulted in improved OS compared with docetaxel in patients with liver metastases (hazard ratio, 0.68; 95% CI, 0.50–0.91), consistent with findings from the overall pooled study population (hazard ratio, 0.70; 95% CI, 0.61–0.81). Rates of treatment-related hepatic adverse events (primarily grade 1–2 liver enzyme elevations) were slightly higher in nivolumab-treated patients with liver metastases (10%) than in the overall pooled population (6%). Conclusions After 3 years' minimum follow-up, nivolumab continued to demonstrate an OS benefit versus docetaxel in patients with advanced NSCLC. Similarly, nivolumab demonstrated an OS benefit versus docetaxel in patients with liver metastases, and remained well tolerated. Clinical trial registration CheckMate 017: NCT01642004; CheckMate 057: NCT01673867

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.This work was supported by Novartis Pharmaceuticals Spain